Skip to main content
Ronald Paquette, MD, Oncology, Los Angeles, CA, Cedars-Sinai Medical Center

RonaldLeoPaquetteMD

Oncology Los Angeles, CA

Professor, Medicine, UCLA School of Medicine

Dr. Paquette is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Paquette's full profile

Already have an account?

Education & Training

  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1987 - 1990
  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1984 - 1987
  • Ohio State University College of Medicine
    Ohio State University College of MedicineClass of 1984

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1987 - 2026
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Super Doctor SuperDoctors.com

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in...
    Ronald Paquette, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

  • Cedars-Sinai’s Stem Cell and Bone Marrow Transplant Program Recognized with Two Major Hallmarks of Quality
    Cedars-Sinai’s Stem Cell and Bone Marrow Transplant Program Recognized with Two Major Hallmarks of QualityJanuary 18th, 2023
  • Hitting Stem Cell and CAR T Targets
    Hitting Stem Cell and CAR T TargetsJanuary 17th, 2023
  • Blood & Marrow Transplant Outcomes Exceed Expectations
    Blood & Marrow Transplant Outcomes Exceed ExpectationsJanuary 18th, 2022

Grant Support

  • Phase I Study Of Recombinant Human Hemoglobin (Rhb1.1) In Patients W/AnemiaNational Center For Research Resources1999–2001
  • Phase I/II Trial Of Recombinant Methionyl Human Stem Cell FactorNational Center For Research Resources1995–1999
  • Phase I Study Of Recombinant Human Hemoglobin (Rhb1.1) In Patients W/Anemia ASSNational Center For Research Resources1998
  • Myeloid Specific Regulation Of IGG FC Receptor Type INational Heart, Lung, And Blood Institute1994–1997
  • Myeloid-Specific Regulation Of IGG FC Receptor Type INational Heart, Lung, And Blood Institute1993

Hospital Affiliations